Global Image Guided Radiation Therapy Market By Product Type (Computed Tomography (CT), Scanners Ultrasound Systems, Magnetic Resonance Imaging (MRI), Endoscope, X-ray Fluoroscopy, Positron Emission Tomography (PET), and Single Photon Emission Computed Tomography (SPECT)), By Application (Breast Cancer, Lung Cancer, Brain Tumor, Prostate Cancer, Gastrointestinal Cancer, Gynecological Cancer, Other Applications), By End-use (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Research & Academic Institutes), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

The Global Image Guided Radiation Therapy Market Size is expected to be worth around US$ 4.3 Billion by 2034, from US$ 2.1 Billion in 2024, growing at a CAGR of 7.4% during the forecast period from 2025 to 2034.

The global image-guided radiation therapy (IGRT) market is driven by several key dynamics shaping its growth trajectory. A primary driver is the rising global incidence of cancer, which is fuelling demand for more precise and effective treatment modalities. IGRT’s ability to deliver highly targeted radiation therapy while minimizing damage to surrounding healthy tissues makes it a preferred choice in modern oncology care.

Technological advancements, such as AI integration, adaptive radiotherapy, and real-time imaging using CT, MRI, and cone-beam CT, are further accelerating adoption. Additionally, growing awareness of early cancer detection and increasing investments in radiation oncology infrastructure particularly in emerging markets are boosting market expansion.

However, high costs of IGRT systems and a shortage of skilled professionals pose significant restraints, particularly in low- and middle-income countries. Reimbursement challenges and uneven access to advanced healthcare technologies also hinder growth in certain regions. Opportunities lie in the expansion of radiation therapy centers, particularly across Asia-Pacific and Latin America, and the development of more cost-effective and compact IGRT solutions.

The market is also witnessing trends such as AI-driven personalization, increased outpatient care, and partnerships between tech companies and healthcare providers. Overall, the IGRT market is poised for steady growth, driven by innovation and the global push for precision cancer treatment.

Key Takeaways

• The global image guided radiation therapy market was valued at USD 2.1 billion in 2024 and is anticipated to register substantial growth of USD 4.3 billion by 2034, with a 7.4% CAGR.
• In 2024, the computed tomography (CT) segment took the lead in the global market, securing 31.2% of the total revenue share.
• The breast cancer segment took the lead in the global market, securing 31.4% of the total revenue share.
• The hospitals segment took the lead in the global market, securing 44.3% of the total revenue share.
• North America maintained its leading position in the global market with a share of over 36.3% of the total revenue.

Product Type Analysis

The global image-guided radiation therapy (IGRT) market is segmented based on product type, including CT scanners, ultrasound systems, MRI, endoscopes, X-ray fluoroscopy, PET, and SPECT. Among these, the computed tomography (CT) segment held a dominant market share of 31.2% in 2024. This growth is driven by its high precision, widespread adoption, and critical role in improving treatment accuracy. CT imaging enables clinicians to localize tumors effectively and adjust radiation doses, reducing damage to healthy tissues. Its compatibility with radiation therapy systems enhances treatment efficiency.

CT imaging plays a vital role in real-time tumor monitoring during radiation therapy. Advanced technologies like 4D-CT and cone-beam CT (CBCT) have improved imaging speed and resolution, allowing better visualization and motion tracking. These advancements help enhance treatment planning and execution. Additionally, the growing global prevalence of cancer has increased the demand for precise diagnostic and therapeutic solutions. This rising need for improved cancer treatment is further fueling the adoption of CT-based IGRT worldwide.

The CT segment’s growth is also supported by continuous technological advancements and new product launches. Several companies are investing in innovative imaging solutions to improve treatment outcomes. The introduction of next-generation CT scanners with enhanced capabilities is driving market expansion. Furthermore, increased awareness among healthcare providers and patients about the benefits of IGRT is boosting demand. As a result, the CT-based IGRT segment is expected to maintain its strong position over the forecast period, contributing significantly to the overall market growth.

• In January 2025, Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, unveiled its AI-enabled CT 5300 at the 23rd Asian Oceanian Congress of Radiology (AOCR) 2025. The company also marked a significant milestone with the global installation of over 1,500 helium-free 1.5T wide bore (70 cm) MRI systems.
• In June 2024, FUJIFILM Healthcare Americas Corporation, a prominent provider of diagnostic and enterprise imaging solutions, announced it had received FDA 510(k) clearance for its latest innovation the FCT iStream, a compact, 128-slice computed tomography (CT) system.

Application Analysis

The market is fragmented by application into breast cancer, lung cancer, brain tumor, prostate cancer, gastrointestinal cancer, gynecological cancer, other applications. The breast cancer segment dominated the global image guided radiation therapy market capturing a significant market share of 31.4% in 2024. ​ The high global prevalence of the disease and the critical role of radiation therapy in breast cancer treatment protocols.

• According to the World Health Organization (WHO), breast cancer was the most diagnosed cancer worldwide in 2023. An estimated 2.3 million new cases were reported. This accounted for 11.6% of all cancer diagnoses. In the United States, the American Cancer Society recorded approximately 297,790 new cases of invasive breast cancer among women in 2023. It remained the most common cancer among American women after skin cancer.

IGRT plays a vital role in breast cancer treatment by enabling precise targeting of the tumor, minimizing radiation exposure to surrounding healthy tissue, and reducing potential side effects. Technological advancements, such as the integration of CT, MRI, and cone-beam CT in radiation therapy, have significantly improved imaging accuracy, contributing to better patient outcomes.

Additionally, increasing awareness, regular screening programs, and favorable reimbursement policies have further boosted the adoption of IGRT in breast cancer treatment. As breast cancer incidence continues to rise globally, the demand for advanced, image-guided therapeutic solutions is expected to remain strong, reinforcing this segment’s dominant position in the market.

End-use Analysis

The market is fragmented by end-use into hospitals, ambulatory surgical centers, specialty clinics, and research & academic institutes. Hospitals held a high share in the global image guided radiation therapy market capturing a significant market share of 44.3% in 2024. Hospitals held a significant share in the global image-guided radiation therapy (IGRT) market due to their comprehensive infrastructure, advanced technological capabilities, and high patient inflow.

These institutions are typically equipped with state-of-the-art imaging and radiotherapy systems, including CT, MRI, and linear accelerators, which are essential for delivering precise and effective IGRT treatments. Hospitals also house multidisciplinary oncology teams, enabling integrated care across diagnostics, treatment planning, and therapy administration. Their ability to manage complex cancer cases, offer inpatient and outpatient services, and conduct clinical trials further supports their leadership in the IGRT space.

Additionally, hospitals often benefit from government funding and favorable reimbursement policies, allowing them to adopt cutting-edge technologies more readily than smaller healthcare facilities. The rising global cancer burden has also increased the number of patients seeking treatment at hospitals, reinforcing their dominant market position. As the demand for accurate, patient-centric cancer therapies grows, hospitals are expected to maintain their stronghold in the IGRT market.

Key Segments Analysis

By Product Type

• Computed Tomography (CT) Scanners
• Ultrasound Systems
• Magnetic Resonance Imaging (MRI)
• Endoscope
• X-ray Fluoroscopy
• Positron Emission Tomography (PET)
• Single Photon Emission Computed Tomography (SPECT)

By Application

• Breast Cancer
• Lung Cancer
• Brain Tumor
• Prostate Cancer
• Gastrointestinal Cancer
• Gynecological Cancer
• Other Applications

By End-use

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Research & Academic Institutes

Drivers

The Rising Prevalence of Target Diseases

The rising global incidence of cancer is a major factor driving the growth of the image-guided radiation therapy (IGRT) market. IGRT plays a crucial role in enhancing radiation therapy outcomes by enabling real-time imaging and accurate tumor targeting, thereby minimizing radiation exposure to surrounding healthy tissues.

• In the United States, the National Cancer Institute (NCI) projected over 1.96 million new cancer cases and approximately 610,000 cancer deaths in 2023, further highlighting the scale of the healthcare challenge.
• According to the International Agency for Research on Cancer (IARC), part of the World Health Organization (WHO), there were an estimated 20 million new cancer cases and 9.7 million cancer-related deaths worldwide in 2023, underscoring the urgent need for effective and precise treatment modalities.

As cancer remains one of the leading causes of mortality globally, the demand for advanced, non-invasive, and highly accurate treatment options like IGRT continues to rise. Moreover, improvements in imaging technologies such as cone-beam CT, MRI, and PET-CT have significantly enhanced the precision and effectiveness of radiation therapy. This increasing cancer burden, combined with technological advancements and growing awareness of image-guided treatments, is propelling the global IGRT market forward, with healthcare providers prioritizing investments in advanced oncology solutions.

Restraints

Lack of Skilled Professionals

The lack of skilled professionals is a significant factor restraining the growth of the global image-guided radiation therapy (IGRT) market. IGRT requires highly trained personnel, including radiation oncologists, medical physicists, and radiologic technologists, to operate advanced imaging systems and deliver precise treatments. However, many healthcare systems, especially in low- and middle-income countries, face a shortage of these specialists, limiting their capacity to adopt and effectively utilize IGRT technologies.

Even in developed regions, the rapid pace of technological advancement has outpaced the availability of adequately trained professionals, creating a skills gap. Operating IGRT systems demands continuous training and upskilling, as new software updates, imaging techniques, and integrated AI tools require specialized knowledge. This workforce constraint can lead to underutilization of installed systems, increased treatment delays, and compromised care quality. As a result, the limited availability of skilled professionals remains a key barrier to the widespread implementation and scalability of IGRT globally.

Opportunities

Expansion of Radiation Oncology Centers

The global expansion of radiation oncology centers is creating significant opportunities for the image-guided radiation therapy (IGRT) market. As healthcare systems strive to meet the rising demand for advanced cancer care, the establishment of new oncology centers especially in emerging markets is accelerating. These centers are increasingly integrating IGRT technologies to deliver precise and personalized treatments, improving patient outcomes.

• According to the American Cancer Society, around 20 million new cancer cases were diagnosed globally in 2022, resulting in 9.7 million deaths, underscoring the urgent need for effective treatment solutions.

IGRT enables accurate tumor localization and real-time imaging during therapy, significantly reducing the risk of damage to healthy tissues. This precision is especially critical in treating complex or hard-to-reach tumors. As more oncology centers adopt such advanced capabilities to meet international treatment standards, the demand for IGRT systems is expected to surge. This trend presents a strong growth opportunity for manufacturers and service providers in the IGRT market.

Impact of Macroeconomic Factors / Geopolitical Factors

Macroeconomic and geopolitical factors have a considerable impact on the image-guided radiation therapy (IGRT) market, influencing both supply and demand dynamics. Economic downturns, inflation, and currency fluctuations can limit healthcare budgets, particularly in developing countries, restricting investment in high-cost technologies like IGRT. Additionally, geopolitical tensions, trade restrictions, and import-export regulations can disrupt global supply chains, delay equipment delivery, and increase operational costs for manufacturers and healthcare providers.

For example, ongoing conflicts or sanctions in regions such as Eastern Europe or the Middle East can hinder infrastructure development and access to advanced medical technologies. Moreover, uncertainty caused by shifting trade policies or regulatory environments can discourage foreign investments in healthcare. On the demand side, healthcare priorities may shift during economic or political crises, delaying cancer care expansion projects. Despite growing cancer prevalence, these macroeconomic and geopolitical pressures can slow the adoption of IGRT systems, especially in markets dependent on international partnerships and imported technology.

Trends

The image guided radiation therapy market is witnessing several emerging trends that are shaping its growth. One of the most notable trends is the increasing demand for patient-friendly drug delivery systems, driven by the growing preference for non-invasive and easy-to-use alternatives to traditional pills and injections. Image Guided Radiation Therapy offer rapid dissolution, improved bioavailability, and convenient administration, making them particularly appealing to patients with chronic conditions or those requiring quick symptom relief.

Additionally, there is a growing focus on developing thin films for a wider range of therapeutic applications, including the delivery of treatments for neurological disorders, pain management, and psychiatric conditions like Cardiac Surgery and Parkinson’s disease. Another trend is the rising use of innovative materials and technologies in the development of Image Guided Radiation Therapy, such as the incorporation of biodegradable polymers and advanced drug encapsulation techniques to enhance the stability and effectiveness of the formulations.

Moreover, the nutraceutical sector is increasingly adopting Image Guided Radiation Therapy for delivering vitamins, supplements, and other health-enhancing products. The market is also seeing a rise in strategic partnerships and collaborations among pharmaceutical companies to advance research and create new oral thin film products. As awareness about the benefits of Image Guided Radiation Therapy grows and research continues to evolve, these trends are expected to fuel further market expansion and innovation.

Regional Analysis

North America held the largest market share in the global image-guided radiation therapy (IGRT) market, driven by its advanced healthcare infrastructure, high prevalence of cancer, and early adoption of innovative technologies. The region benefits from well-established oncology centers, a strong presence of leading medical device manufacturers, and significant investments in research and development. Favourable reimbursement policies, supportive government initiatives, and continuous technological advancements such as AI integration and adaptive radiotherapy have further accelerated the adoption of IGRT systems.

Additionally, the availability of skilled professionals and growing awareness about precision cancer treatment contribute to the region’s market leadership. With a strong focus on improving patient outcomes and reducing treatment side effects, North America is expected to maintain its dominant position in the global IGRT market.

Asia-Pacific held the second-largest market share in the global image-guided radiation therapy (IGRT) market, driven by a rapidly growing cancer burden, expanding healthcare infrastructure, and increased government investment in oncology services. Countries such as China, India, and Japan are witnessing a significant rise in cancer incidence, prompting greater demand for advanced and precise treatment options such as IGRT. According to the World Health Organization, Asia accounts for nearly half of global cancer cases, making it a key region for radiation therapy advancements.

The growing adoption of cutting-edge medical technologies, rising awareness of early cancer detection and treatment, and favorable government initiatives are further accelerating IGRT implementation. Additionally, the presence of a large patient pool, coupled with increasing healthcare expenditure and the expansion of radiation oncology centers, has positioned Asia-Pacific as a leading market. Local manufacturing capabilities and strategic collaborations are also enhancing accessibility and affordability, fuelling further market growth in the region.

• In China, cancer has become a major public health concern. According to the National Cancer Center of China, the country recorded approximately 4.82 million new cancer cases and 3.21 million cancer-related deaths in 2022. Lung, colorectal, stomach, liver, and breast cancers are among the most commonly diagnosed types. Rapid urbanization, lifestyle changes, aging population, and environmental factors have contributed to the rising cancer prevalence.

Key Regions and Countries

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Russia
  • Netherland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • New Zealand
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA

Key Players Analysis

The competitive landscape of the image-guided radiation therapy (IGRT) market is characterized by the presence of several global players striving to enhance their technological capabilities, expand their geographic reach, and strengthen their market position. Key companies such as Varian Medical Systems (a Siemens Healthineers company), Elekta AB, Accuray Incorporated, ViewRay, and Brainlab lead the market with a strong focus on innovation in precision imaging, adaptive radiotherapy, and AI integration.

These firms consistently invest in R&D to develop advanced imaging-guided solutions that improve treatment accuracy and patient outcomes. Strategic collaborations, mergers and acquisitions, and partnerships with hospitals and cancer centers are common strategies to gain a competitive edge. Additionally, emerging players and regional manufacturers in Asia-Pacific are intensifying competition by offering cost-effective solutions.

As the global cancer burden rises and healthcare providers seek more efficient and precise treatment options, competition in the IGRT market is expected to grow further, driving continuous technological advancement. Siemens Healthineers AG, a division of Siemens AG, is a leading global medical technology company headquartered in Erlangen, Germany. It specializes in diagnostic and therapeutic imaging, laboratory diagnostics, and advanced digital health solutions. With a strong presence in over 70 countries, Siemens Healthineers is known for its innovation in MRI, CT, ultrasound, and radiotherapy technologies.

The company plays a vital role in transforming healthcare delivery through AI-powered diagnostics, precision medicine, and integrated care solutions. In addition, Medtronic plc is a global leader in medical technology, services, and solutions, headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, the company operates in over 150 countries and focuses on improving healthcare through innovative therapies across cardiac, neurological, spinal, and diabetes-related conditions.

Top Key Players in the Image Guided Radiation Therapy Market

• Philips
• Medtronic
• Siemens Healthineers
• Analogic Corporation
• GE Healthcare
• Varian Medical Systems Inc.
• Brainlab AG
• Olympus Corporation
• Stryker
• GE HealthCare

Recent Developments

• In October 2024: Philips and Medtronic Neurovascular announced a strategic partnership focused on improving access to timely stroke care. The collaboration aims to raise awareness, expand treatment availability, and utilize advanced technologies—including image-guided therapy systems—to enhance stroke diagnosis and intervention. Both companies have also deepened their collaboration with the World Stroke Organization by joining the WSO Advocacy Coalition, reinforcing their commitment to addressing the global burden of stroke.
• In October 2024: GE HealthCare introduced the Versana Premier, a versatile ultrasound system designed to boost clinical efficiency across specialties such as obstetrics and gynecology (OBGYN), musculoskeletal (MSK), and cardiology. The system incorporates AI-powered tools to streamline workflows and improve diagnostic accuracy. Featuring VisionBoost Architecture and XDclear probes, it delivers exceptional image clarity. Its ergonomic design and automation capabilities aim to simplify diagnostics and complement image-guided therapy systems in diverse clinical applications by providing faster and more precise imaging.
• In September 2024: Medtronic expanded its AiBLE ecosystem for spine surgery through new technologies and a partnership with Siemens Healthineers. This collaboration integrates advanced imaging, navigation, and AI to enhance the precision and efficiency of image-guided therapy in spinal procedures. Key innovations include AI-powered tools for personalized surgical planning and enhanced visualization for real-time decision-making.

Report Scope